Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética
| Ano de defesa: | 2021 |
|---|---|
| Autor(a) principal: | |
| Orientador(a): | |
| Banca de defesa: | , , , |
| Tipo de documento: | Tese |
| Tipo de acesso: | Acesso aberto |
| Idioma: | por |
| Instituição de defesa: |
Universidade Federal de Alfenas
|
| Programa de Pós-Graduação: |
Programa de Pós-Graduação em Ciências Farmacêuticas
|
| Departamento: |
Faculdade de Ciências Farmacêuticas
|
| País: |
Brasil
|
| Palavras-chave em Português: | |
| Área do conhecimento CNPq: | |
| Link de acesso: | https://repositorio.unifal-mg.edu.br/handle/123456789/1816 |
Resumo: | Neuropathic pain is a type of chronic pain, in which damage occurs to the somatosensory nervous system and is difficult to treat. A controlled release system can change the pharmacokinetic parameters of the substance, reducing side effects and increasing adherence to treatment. Thus, the aim of this work was to obtain and characterize polymeric nanoparticles with pregabalin (PG), and to verify its pharmacokinetics, nociception potential and side effect (drowsiness) of this formulation. For this, polymeric nanoparticles with PG were developed using the ionotropic gelling method, between chitosan and hydroxypropylmethylcellulose phthalate. The particles showed an average particle size of 432 nm, with good homogeneity in particle size spherical shape, the average zeta potential of +19.0 mV and the average pH of 5.7. The formulation showed an association rate of approximately 44%. X-ray diffraction, thermogravimetry and differential exploratory calorimetry tests suggested the formation of the polymeric nanoparticles with PG. The Fourier transform infrared spectroscopy test confirmed the interaction form of the nanoparticles. For the evaluation of pharmacokinetics, antinociceptive effect, motor coordination, locomotor behavior and side effect, male Wistar rats (220-250 g) were used and divided into 4 groups: polymeric nanoparticle with PG (NP PG), PG, empty nanoparticle (NP VAZ) and ultrapure water (WATER), and received the substances orally, in a single dose (10 mg/Kg). To calculate the pharmacokinetic parameters, plasma concentrations were determined by UPLC-MS/MS. PG NP showed increased volume of distribution and clearance compared to PG. To evaluate the antinociceptive effect, the animals underwent induction of neuropathic pain by chronic sciatic nerve constriction (CCI) in the right paw and received the substances on day 14 after CCI and mechanical allodynia was tested only in the right paw before CCI and on day 14: before administration of the substances, 1, 2:15, 4, 8, 24, 48 and 72 h after administration of the substances. When we compared the CCI-PG and CCI-NP PG groups with CCI-WATER, the CCI-PG group showed an antinociceptive effect at 1 to 8 h and the CCI-NP PG group at 1 to 48 h after the administration of the substances. When we compared CCI-NP PG with CCI-PG, the antinociceptive profile of the groups only differed at 48 h after the administration of the substances, showing that NP PG still maintained the positive effect in reducing nociception. The results of the rota-rod showed that none of the substances caused motor deficit in any of the tested times. The results of the open field showed the same profile of reduced exploration over time with all substances administered. The drowsiness results showed that both the PG and NP PG groups showed sedative effects, when compared to the WATER and NP VAZ groups; with the duration of the sedative effect of NP PG significantly shorter than that of PG. Thus, the administration of PG through polymeric nanoparticles showed prolongation of the antinociceptive effect, longer duration of stay in the body and reduction of side effects. |
| id |
UNIFAL_cd7389431e43fdc5a11b60beb1c0c535 |
|---|---|
| oai_identifier_str |
oai:repositorio.unifal-mg.edu.br:123456789/1816 |
| network_acronym_str |
UNIFAL |
| network_name_str |
Repositório Institucional da Universidade Federal de Alfenas - RiUnifal |
| repository_id_str |
|
| spelling |
Rodrigues, Rafaela Figueiredohttp://lattes.cnpq.br/8780898275430944Souza, Giovane Galdino DeBernardi, Juliana CancinoRomero, Thiago Roberto LimaPereira, Gislaine RibeiroSilva, Josie Resende Torres DaMarques, Vanessa Bergamin Borallihttp://lattes.cnpq.br/24513126295019312021-06-21T19:54:24Z2022-06-232021-03-24RODRIGUES, Rafaela Figueiredo. Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética. 2021. 176 f. Tese (Doutorado em Ciências Farmacêuticas) - Universidade Federal de Alfenas, Alfenas, MG, 2021.https://repositorio.unifal-mg.edu.br/handle/123456789/1816Neuropathic pain is a type of chronic pain, in which damage occurs to the somatosensory nervous system and is difficult to treat. A controlled release system can change the pharmacokinetic parameters of the substance, reducing side effects and increasing adherence to treatment. Thus, the aim of this work was to obtain and characterize polymeric nanoparticles with pregabalin (PG), and to verify its pharmacokinetics, nociception potential and side effect (drowsiness) of this formulation. For this, polymeric nanoparticles with PG were developed using the ionotropic gelling method, between chitosan and hydroxypropylmethylcellulose phthalate. The particles showed an average particle size of 432 nm, with good homogeneity in particle size spherical shape, the average zeta potential of +19.0 mV and the average pH of 5.7. The formulation showed an association rate of approximately 44%. X-ray diffraction, thermogravimetry and differential exploratory calorimetry tests suggested the formation of the polymeric nanoparticles with PG. The Fourier transform infrared spectroscopy test confirmed the interaction form of the nanoparticles. For the evaluation of pharmacokinetics, antinociceptive effect, motor coordination, locomotor behavior and side effect, male Wistar rats (220-250 g) were used and divided into 4 groups: polymeric nanoparticle with PG (NP PG), PG, empty nanoparticle (NP VAZ) and ultrapure water (WATER), and received the substances orally, in a single dose (10 mg/Kg). To calculate the pharmacokinetic parameters, plasma concentrations were determined by UPLC-MS/MS. PG NP showed increased volume of distribution and clearance compared to PG. To evaluate the antinociceptive effect, the animals underwent induction of neuropathic pain by chronic sciatic nerve constriction (CCI) in the right paw and received the substances on day 14 after CCI and mechanical allodynia was tested only in the right paw before CCI and on day 14: before administration of the substances, 1, 2:15, 4, 8, 24, 48 and 72 h after administration of the substances. When we compared the CCI-PG and CCI-NP PG groups with CCI-WATER, the CCI-PG group showed an antinociceptive effect at 1 to 8 h and the CCI-NP PG group at 1 to 48 h after the administration of the substances. When we compared CCI-NP PG with CCI-PG, the antinociceptive profile of the groups only differed at 48 h after the administration of the substances, showing that NP PG still maintained the positive effect in reducing nociception. The results of the rota-rod showed that none of the substances caused motor deficit in any of the tested times. The results of the open field showed the same profile of reduced exploration over time with all substances administered. The drowsiness results showed that both the PG and NP PG groups showed sedative effects, when compared to the WATER and NP VAZ groups; with the duration of the sedative effect of NP PG significantly shorter than that of PG. Thus, the administration of PG through polymeric nanoparticles showed prolongation of the antinociceptive effect, longer duration of stay in the body and reduction of side effects.A dor neuropática é um tipo de dor crônica, em que ocorre lesão no sistema nervoso somatossensorial e é difícil de ser tratada. Um sistema de liberação controlada pode alterar os parâmetros farmacocinéticos da substância, reduzindo os efeitos colaterais, aumentando adesão ao tratamento. Desta forma, o objetivo deste trabalho foi obter e caracterizar nanopartículas poliméricas com pregabalina (PG), além de verificar sua farmacocinética, seu potencial de nocicepção e o efeito colateral (sonolência) desta formulação. Para isso, as nanopartículas poliméricas com PG foram desenvolvidas utilizando-se o método de geleificação ionotrópica, entre quitosana e ftalato de hidroxipropilmetilcelulose. As partículas apresentaram um tamanho médio de 432 nm, com boa homogeneidade no tamanho das partículas forma esférica, o potencial zeta médio de +19,0 mV e o pH médio de 5,7. A formulação apresentou taxa de associação de aproximadamente 44%. Os testes de difração de raios-X, termogravimetria e calorimetria exploratória diferencial sugeriram a formação das nanopartículas poliméricas com PG. O teste de espectroscopia no infravermelho com transformada de Fourier confirmou a forma de interação das nanopartículas. Para a avaliação da farmacocinética, do efeito antinociceptivo, coordenação motora, comportamento locomotor e efeito colateral foram utilizados ratos Wistar machos (220-250 g), divididos em 4 grupos: nanopartícula polimérica com PG (NP PG), PG, nanopartícula vazia (NP VAZ) e água ultrapura (ÁGUA), e receberam as substâncias por via oral, em dose única (10 mg/Kg). Para o cálculo dos parâmetros farmacocinéticos, as concentrações plasmáticas foram determinadas por UPLC-MS/MS. A NP PG apresentou aumento no volume de distribuição e no clearance comparada à PG. Para a avaliação do efeito antinociceptivo, os animais passaram pela indução da dor neuropática através da constrição crônica do nervo ciático (CCI) na pata direita e receberam as substâncias no 14° dia após a CCI e a alodinia mecânica foi testada apenas na pata direita antes da CCI e no 14° dia: antes da administração das substâncias, 1, 2:15, 4, 8, 24, 48 e 72 h após a administração das substâncias. Quando comparamos os grupos CCI-PG e CCI-NP PG com CCI-ÁGUA o grupo CCI-PG apresentou efeito antinociceptivo em 1 a 8 h e o grupo CCI-NP PG em 1 a 48 h, após a administração das substâncias. Quando comparamos CCI-NP PG com CCI-PG, o perfil antinociceptivo dos grupos só diferiu no tempo de 48 horas após a administração das substâncias, mostrando que a NP PG ainda mantia o efeito positivo em redução da nocicepção. Os resultados do rota-rod mostraram que nenhuma das substâncias ocasionou déficit motor em nenhum dos tempos testados. Os resultados do campo aberto mostraram o mesmo perfil de redução de exploração ao longo do tempo, com todas as substâncias administradas. Os resultados da sonolência demonstraram que tanto o grupo PG quanto o NP PG apresentaram efeitos sedativos, quando comparados com os grupos ÁGUA e NP VAZ; com duração do efeito sedativo da NP PG significativamente menor que da PG. Assim, a administração de PG através de nanopartículas poliméricas apresentou prolongamento do efeito antinociceptivo, maior tempo de permanência no organismo e redução de efeitos colaterais.Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIGapplication/pdfporUniversidade Federal de AlfenasPrograma de Pós-Graduação em Ciências FarmacêuticasUNIFAL-MGBrasilFaculdade de Ciências Farmacêuticasinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/Tratamento da dor neuropáticaNeuropatiaEstudo pré-clínicoNanopartícula poliméricaQuitosanaFarmacocinética - PregabalinaCIENCIAS DA SAUDE::FARMACIANanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinéticainfo:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/publishedVersion-64258451559862442976006006006997636413449754996-1527361517405938873reponame:Repositório Institucional da Universidade Federal de Alfenas - RiUnifalinstname:Universidade Federal de Alfenas (UNIFAL)instacron:UNIFALRodrigues, Rafaela FigueiredoCC-LICENSElicense_urllicense_urltext/plain; charset=utf-849https://repositorio.unifal-mg.edu.br/bitstreams/dc419cb5-3687-469e-a8d1-e6e5d224e612/download4afdbb8c545fd630ea7db775da747b2fMD52license_textlicense_texttext/html; charset=utf-80https://repositorio.unifal-mg.edu.br/bitstreams/4d29475a-815a-4acb-b14a-c9937c6d1623/downloadd41d8cd98f00b204e9800998ecf8427eMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-80https://repositorio.unifal-mg.edu.br/bitstreams/8e79368c-9c05-41fd-9d2d-e43151163a12/downloadd41d8cd98f00b204e9800998ecf8427eMD54ORIGINALTese Rafaela Figueiredo Rodrigues.pdfTese Rafaela Figueiredo Rodrigues.pdfapplication/pdf3131122https://repositorio.unifal-mg.edu.br/bitstreams/e5ffe526-86d6-4899-8412-c71649cda659/download3a11bdea680f1c83b8eb613770d5e48aMD55LICENSElicense.txtlicense.txttext/plain; charset=utf-81987https://repositorio.unifal-mg.edu.br/bitstreams/c6b2a929-a8f3-4c7a-a46a-774b6cf295e2/download31555718c4fc75849dd08f27935d4f6bMD51TEXTTese Rafaela Figueiredo Rodrigues.pdf.txtTese Rafaela Figueiredo Rodrigues.pdf.txtExtracted texttext/plain103211https://repositorio.unifal-mg.edu.br/bitstreams/23e92eb2-e277-4eb9-b33c-63865a4d58f6/downloadd5a01fba6fc88f3ad4ad2b9c49812587MD510THUMBNAILTese Rafaela Figueiredo Rodrigues.pdf.jpgTese Rafaela Figueiredo Rodrigues.pdf.jpgGenerated Thumbnailimage/jpeg2592https://repositorio.unifal-mg.edu.br/bitstreams/530201bc-b625-4a19-ace8-f7e08d06bda3/download57edbe892479425b96f9d7dab505d714MD59123456789/18162026-03-06 13:41:58.471http://creativecommons.org/licenses/by-nc-nd/4.0/open.accessoai:repositorio.unifal-mg.edu.br:123456789/1816https://repositorio.unifal-mg.edu.brRepositório InstitucionalPUBhttps://bdtd.unifal-mg.edu.br:8443/oai/requestrepositorio@unifal-mg.edu.bropendoar:2026-03-06T16:41:58Repositório Institucional da Universidade Federal de Alfenas - RiUnifal - Universidade Federal de Alfenas (UNIFAL)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 |
| dc.title.pt-BR.fl_str_mv |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| title |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| spellingShingle |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética Rodrigues, Rafaela Figueiredo Tratamento da dor neuropática Neuropatia Estudo pré-clínico Nanopartícula polimérica Quitosana Farmacocinética - Pregabalina CIENCIAS DA SAUDE::FARMACIA |
| title_short |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| title_full |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| title_fullStr |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| title_full_unstemmed |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| title_sort |
Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética |
| author |
Rodrigues, Rafaela Figueiredo |
| author_facet |
Rodrigues, Rafaela Figueiredo |
| author_role |
author |
| dc.contributor.author.fl_str_mv |
Rodrigues, Rafaela Figueiredo |
| dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/8780898275430944 |
| dc.contributor.advisor-co1.fl_str_mv |
Souza, Giovane Galdino De |
| dc.contributor.referee1.fl_str_mv |
Bernardi, Juliana Cancino |
| dc.contributor.referee2.fl_str_mv |
Romero, Thiago Roberto Lima |
| dc.contributor.referee3.fl_str_mv |
Pereira, Gislaine Ribeiro |
| dc.contributor.referee4.fl_str_mv |
Silva, Josie Resende Torres Da |
| dc.contributor.advisor1.fl_str_mv |
Marques, Vanessa Bergamin Boralli |
| dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/2451312629501931 |
| contributor_str_mv |
Souza, Giovane Galdino De Bernardi, Juliana Cancino Romero, Thiago Roberto Lima Pereira, Gislaine Ribeiro Silva, Josie Resende Torres Da Marques, Vanessa Bergamin Boralli |
| dc.subject.por.fl_str_mv |
Tratamento da dor neuropática Neuropatia Estudo pré-clínico Nanopartícula polimérica Quitosana Farmacocinética - Pregabalina |
| topic |
Tratamento da dor neuropática Neuropatia Estudo pré-clínico Nanopartícula polimérica Quitosana Farmacocinética - Pregabalina CIENCIAS DA SAUDE::FARMACIA |
| dc.subject.cnpq.fl_str_mv |
CIENCIAS DA SAUDE::FARMACIA |
| description |
Neuropathic pain is a type of chronic pain, in which damage occurs to the somatosensory nervous system and is difficult to treat. A controlled release system can change the pharmacokinetic parameters of the substance, reducing side effects and increasing adherence to treatment. Thus, the aim of this work was to obtain and characterize polymeric nanoparticles with pregabalin (PG), and to verify its pharmacokinetics, nociception potential and side effect (drowsiness) of this formulation. For this, polymeric nanoparticles with PG were developed using the ionotropic gelling method, between chitosan and hydroxypropylmethylcellulose phthalate. The particles showed an average particle size of 432 nm, with good homogeneity in particle size spherical shape, the average zeta potential of +19.0 mV and the average pH of 5.7. The formulation showed an association rate of approximately 44%. X-ray diffraction, thermogravimetry and differential exploratory calorimetry tests suggested the formation of the polymeric nanoparticles with PG. The Fourier transform infrared spectroscopy test confirmed the interaction form of the nanoparticles. For the evaluation of pharmacokinetics, antinociceptive effect, motor coordination, locomotor behavior and side effect, male Wistar rats (220-250 g) were used and divided into 4 groups: polymeric nanoparticle with PG (NP PG), PG, empty nanoparticle (NP VAZ) and ultrapure water (WATER), and received the substances orally, in a single dose (10 mg/Kg). To calculate the pharmacokinetic parameters, plasma concentrations were determined by UPLC-MS/MS. PG NP showed increased volume of distribution and clearance compared to PG. To evaluate the antinociceptive effect, the animals underwent induction of neuropathic pain by chronic sciatic nerve constriction (CCI) in the right paw and received the substances on day 14 after CCI and mechanical allodynia was tested only in the right paw before CCI and on day 14: before administration of the substances, 1, 2:15, 4, 8, 24, 48 and 72 h after administration of the substances. When we compared the CCI-PG and CCI-NP PG groups with CCI-WATER, the CCI-PG group showed an antinociceptive effect at 1 to 8 h and the CCI-NP PG group at 1 to 48 h after the administration of the substances. When we compared CCI-NP PG with CCI-PG, the antinociceptive profile of the groups only differed at 48 h after the administration of the substances, showing that NP PG still maintained the positive effect in reducing nociception. The results of the rota-rod showed that none of the substances caused motor deficit in any of the tested times. The results of the open field showed the same profile of reduced exploration over time with all substances administered. The drowsiness results showed that both the PG and NP PG groups showed sedative effects, when compared to the WATER and NP VAZ groups; with the duration of the sedative effect of NP PG significantly shorter than that of PG. Thus, the administration of PG through polymeric nanoparticles showed prolongation of the antinociceptive effect, longer duration of stay in the body and reduction of side effects. |
| publishDate |
2021 |
| dc.date.accessioned.fl_str_mv |
2021-06-21T19:54:24Z |
| dc.date.issued.fl_str_mv |
2021-03-24 |
| dc.date.available.fl_str_mv |
2022-06-23 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
doctoralThesis |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
RODRIGUES, Rafaela Figueiredo. Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética. 2021. 176 f. Tese (Doutorado em Ciências Farmacêuticas) - Universidade Federal de Alfenas, Alfenas, MG, 2021. |
| dc.identifier.uri.fl_str_mv |
https://repositorio.unifal-mg.edu.br/handle/123456789/1816 |
| identifier_str_mv |
RODRIGUES, Rafaela Figueiredo. Nanopartículas poliméricas com pregabalina para o tratamento de dor neuropática em ratos: obtenção, caracterização e avaliação in vivo do efeito antinociceptivo e da farmacocinética. 2021. 176 f. Tese (Doutorado em Ciências Farmacêuticas) - Universidade Federal de Alfenas, Alfenas, MG, 2021. |
| url |
https://repositorio.unifal-mg.edu.br/handle/123456789/1816 |
| dc.language.iso.fl_str_mv |
por |
| language |
por |
| dc.relation.department.fl_str_mv |
-6425845155986244297 |
| dc.relation.confidence.fl_str_mv |
600 600 600 |
| dc.relation.cnpq.fl_str_mv |
6997636413449754996 |
| dc.relation.sponsorship.fl_str_mv |
-1527361517405938873 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidade Federal de Alfenas |
| dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências Farmacêuticas |
| dc.publisher.initials.fl_str_mv |
UNIFAL-MG |
| dc.publisher.country.fl_str_mv |
Brasil |
| dc.publisher.department.fl_str_mv |
Faculdade de Ciências Farmacêuticas |
| publisher.none.fl_str_mv |
Universidade Federal de Alfenas |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal de Alfenas - RiUnifal instname:Universidade Federal de Alfenas (UNIFAL) instacron:UNIFAL |
| instname_str |
Universidade Federal de Alfenas (UNIFAL) |
| instacron_str |
UNIFAL |
| institution |
UNIFAL |
| reponame_str |
Repositório Institucional da Universidade Federal de Alfenas - RiUnifal |
| collection |
Repositório Institucional da Universidade Federal de Alfenas - RiUnifal |
| bitstream.url.fl_str_mv |
https://repositorio.unifal-mg.edu.br/bitstreams/dc419cb5-3687-469e-a8d1-e6e5d224e612/download https://repositorio.unifal-mg.edu.br/bitstreams/4d29475a-815a-4acb-b14a-c9937c6d1623/download https://repositorio.unifal-mg.edu.br/bitstreams/8e79368c-9c05-41fd-9d2d-e43151163a12/download https://repositorio.unifal-mg.edu.br/bitstreams/e5ffe526-86d6-4899-8412-c71649cda659/download https://repositorio.unifal-mg.edu.br/bitstreams/c6b2a929-a8f3-4c7a-a46a-774b6cf295e2/download https://repositorio.unifal-mg.edu.br/bitstreams/23e92eb2-e277-4eb9-b33c-63865a4d58f6/download https://repositorio.unifal-mg.edu.br/bitstreams/530201bc-b625-4a19-ace8-f7e08d06bda3/download |
| bitstream.checksum.fl_str_mv |
4afdbb8c545fd630ea7db775da747b2f d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e 3a11bdea680f1c83b8eb613770d5e48a 31555718c4fc75849dd08f27935d4f6b d5a01fba6fc88f3ad4ad2b9c49812587 57edbe892479425b96f9d7dab505d714 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal de Alfenas - RiUnifal - Universidade Federal de Alfenas (UNIFAL) |
| repository.mail.fl_str_mv |
repositorio@unifal-mg.edu.br |
| _version_ |
1859830870493364224 |